证券代码：000615 证券简称：*ST美谷 公告编号：2025-069 奥园美谷科技股份有限公司 关于公司收到债权及担保权利转让暨催收通知的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 奥园美谷科技股份有限公司（以下简称"公司"）于 2025 年 7 月 30 日收到 中国民生银行股份有限公司广州分行（以下简称"民生银行""转让方"）和中 国信达资产管理股份有限公司广东省分公司（以下简称"信达资管""受让方"） 出具的《债权及担保权利转让暨催收通知》（（2025）民生信达粤 03 号），现 将相关事项公告如下： 一、债权及担保权利转让与催收通知的主要内容 根据中国民生银行股份有限公司广州分行与中国信达资产管理股份有限公 司广东省分公司达成的资产转让协议，转让方将其对下文清单所列借款人及其担 保人享有的主债权及借款合同、担保合同等其他相关协议项下的全部权利，依法 转让给受让方。 现转让方及受让方共同以邮寄送达的方式通知各借款人、担保人以及借款人、 担保人因各种原因发生更名、改制、歇业、吊销营业执照或丧失民事主体资格等 情况的相关承债主体或清算主体上述债 ...

证券之星消息，7月30日医疗美容板块较上一交易日上涨0.5%，爱美客领涨。当日上证指数报收于 3615.72，上涨0.17%。深证成指报收于11203.03，下跌0.77%。医疗美容板块个股涨跌见下表： | 代码 | | | 名称 | | | | | --- | --- | --- | --- | --- | --- | --- | | 688363 华熙生物 | 209.44万 | 0.80% | -309.19万 | -1.19% | 99.75万 | 0.38% | | 000615 *ST美谷 | -221.92万 | -10.61% | -76.08万 | -3.64% | 298.00万 | 14.25% | | 300896 爱美客 | -1295.20万 | -1.73% | 3414.81万 | 4.56% | -2119.61万 | -2.83% | 从资金流向上来看，当日医疗美容板块主力资金净流出1307.69万元，游资资金净流入3029.54万元，散户 资金净流出1721.85万元。医疗美容板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104 ...

Group 1 - The medical beauty sector experienced a decline of 0.17% on July 29, with Ai Meike leading the drop [1] - The Shanghai Composite Index closed at 3609.71, up 0.33%, while the Shenzhen Component Index closed at 11289.41, up 0.64% [1] - Major stocks in the medical beauty sector showed mixed performance, with Jinbo Biological up 1.82% and Ai Meike down 0.73% [1] Group 2 - The medical beauty sector saw a net outflow of 37.97 million yuan from main funds, while retail investors contributed a net inflow of 56.99 million yuan [1] - Specific stock performances included Huaxi Biological with a net outflow of 1.47 million yuan and *ST Meigu with a net inflow of 0.55 million yuan [2]

Group 1 - The medical beauty market in China is experiencing continuous growth, with the number of compliant specialized medical beauty institutions reaching 19,880 in the first half of 2024, an increase of 1,296 institutions or 7% from January 2024 [1][3] - The increase in compliant medical beauty institutions is driven by enhanced regulatory oversight and a growing consumer demand for legitimate medical beauty services [1][3] Group 2 - There is a significant shortage of compliant medical beauty doctors, with an estimated gap of around 20,000 qualified professionals, while the total number of medical beauty practitioners is approximately 1.02 million [4] - The annual growth rate of medical beauty practitioners is around 10%, but the supply of qualified professionals is only increasing at a rate of 5%-8%, highlighting a supply-demand imbalance [4] Group 3 - The distribution of medical beauty positions in China shows a clear imbalance, with only 10% of positions being medical technical roles, which require solid medical knowledge and qualifications [6] - Over 60% of positions are in marketing and operations, which are crucial for attracting customers and driving business growth, but this focus may compromise the quality of medical services [6] Group 4 - The educational requirements for core positions in the medical beauty industry are increasing, with a trend towards higher educational qualifications among professionals [9] - Large medical beauty companies are setting stricter educational standards, with some requiring a full-time bachelor's degree for medical technical roles [9] Group 5 - The distribution of medical beauty talent in China shows a pattern of concentration in eastern regions and high-tier cities, with first-tier cities holding over 50% of medical beauty positions [10] - New first-tier cities are competing for mid-level talent through differentiated strategies, while lower-tier cities struggle due to a lack of local training capabilities [10]

证券代码：000615 证券简称：*ST美谷 公告编号：2025-068 奥园美谷科技股份有限公司 关于重大仲裁事项进展暨收到《执行通知书》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次案件所处的诉讼（仲裁）阶段：执行； 2、上市公司所处的当事人地位：被申请人； 3、涉案的金额：135,306,299.04 元（不含仲裁费）； 4、对上市公司损益产生的影响：公司将根据企业会计准则的相关规定和诉 讼案件等情况进行财务处理，具体处理结果以及对公司本期期末业绩的影响，以 会计师事务所最终年度审计结果为准。 敬请广大投资者注意投资风险。 一、定向融资计划仲裁案的基本情况 京汉控股集团有限公司（以下简称"京汉控股""申请人"）因定向融资计 划向北京仲裁委员会申请仲裁，仲裁请求为：请求裁决被申请人一京汉置业集团 有限责任公司（以下简称"京汉置业"）向申请人支付"京汉置业 2021 年定向 融资计划三期"产品剩余本金人民币 8,820 万元；裁决被申请人一向申请人支付 逾期支付"京汉置业 2021 年定向融资计划三期"产品剩余本金的违约金（以应 ...

Core Viewpoint - The company is currently involved in a lawsuit initiated by China Cinda Asset Management Co., Ltd. due to a debt transfer contract dispute, which may have significant financial implications for the company [1][2][3]. Group 1: Lawsuit Details - The lawsuit involves a claim for the repayment of a principal amount of 33,152,354.74 yuan along with penalties and interest, with the company and several other defendants being held jointly liable [1][2]. - The court has ordered the company to pay a total of 200,000 yuan in legal fees and has established joint liability for the repayment of the debt among the defendants [2][3]. - The case has been transferred to the Guangzhou Tianhe District People's Court for further proceedings [2]. Group 2: Financial Impact - The company has already made provisions for expected liabilities related to this lawsuit, which will be reflected in the 2024 annual report [3]. - The financial outcome of the lawsuit will depend on the final audit results from the accounting firm, as the company will follow relevant accounting standards for financial treatment [3]. Group 3: Asset Implications - The lawsuit has led to the freezing of certain assets, and there is a risk of judicial disposal of assets as some cases have entered the enforcement stage [5]. - The company has been listed as a dishonest executor by the court, which may affect its operations and future legal standing [5]. Group 4: Stock Market Impact - The company is facing potential delisting risk warnings due to the ongoing legal issues, which could affect its stock trading status [6]. - The company has been advised to disclose information regarding the delisting risk and other warnings to investors [6].

证券代码：000615 证券简称：*ST美谷 公告编号：2025-067 奥园美谷科技股份有限公司 关于重大诉讼事项进展暨收到《民事判决书》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次案件所处的诉讼阶段：一审判决； 2、上市公司所处的当事人地位：被告； 3、对上市公司损益产生的影响：公司将根据企业会计准则的相关规定和诉 讼案件等情况进行财务处理，具体处理结果以及对公司本期期末业绩的影响，以 会计师事务所最终年度审计结果为准。 4、敬请广大投资者关注风险提示内容，谨慎决策、注意投资风险。 一、诉讼案件的基本情况 信达资产管理股份有限公司广东省分公司（以下简称"信达资管"、原告） 因债权转让合同纠纷向河北省廊坊市安次区人民法院提起诉讼，案号（2023）冀 1002 民初 1431 号，诉讼请求为：判令被告保定京汉君庭酒店有限公司偿还原告 借款本金 33,152,354.74 元及罚息、复利；判令被告奥园美谷科技股份有限公司 （以下简称"公司"）、奥园集团有限公司、广州康威集团有限公司、惠州狮峰 实业有限公司、深圳奥园科星投资有限公司 ...

Group 1 - The article provides an overview of the Chinese medical beauty industry, highlighting key listed companies and their performance metrics [1][5][9] - Major players in the industry include Aimeike, Huaxi Biological, and Haohai Biological, with Aimeike maintaining the highest market share in the sodium hyaluronate filler market since 2018 [3][5] - The industry is characterized by a diverse supply chain, with upstream raw material manufacturers, midstream medical institutions, and downstream consumers [1][7] Group 2 - In 2024, Aimeike reported a revenue of 30.26 billion, while Huaxi Biological achieved 53.71 billion, indicating strong performance among leading companies [5][10] - The article notes that Aimeike has a gross profit margin exceeding 90%, outperforming other companies in the sector [9][10] - Companies are focusing on R&D innovation and brand building to enhance market competitiveness and meet evolving consumer demands [11][13] Group 3 - The geographical distribution of companies shows a concentration in coastal regions, particularly in major cities like Beijing, Shanghai, and Guangzhou, which host top research institutions and production companies [7] - Companies like Huadong Pharmaceutical and Huaxi Biological primarily focus on domestic sales, while others like Langzi and Huakan have diversified regional strategies [9][10] - Future plans for companies include enhancing R&D capabilities, expanding production projects, and improving customer service to create a win-win ecosystem [11][13]

Core Viewpoint - The company, Aoyuan Meigu Technology Co., Ltd., is currently involved in a lawsuit regarding a financing lease contract dispute, which may have significant implications for its financial performance and obligations [1][3]. Group 1: Lawsuit Details - The lawsuit was initiated by Zhejiang Zhiyin Financial Leasing Co., Ltd. against multiple defendants, including Aoyuan Meigu and its subsidiaries, for unpaid lease payments totaling 44,188,335.10 yuan, along with overdue penalties of 654,700.79 yuan [2]. - The court has ordered the defendants to pay the outstanding lease payments and associated legal fees, and has granted the plaintiff priority rights over the leased assets and certain receivables [2]. Group 2: Financial Implications - The overdue debts of the company's subsidiary, Hubei Jinhui New Materials Technology Co., Ltd., have not been repaid on time, which may affect the company's financial standing [3]. - The impact of the ongoing lawsuit on the company's current and future profits remains uncertain, and the company will assess the situation based on accounting standards and actual circumstances [3]. Group 3: Other Legal Matters - As of the announcement date, there are no other undisclosed significant lawsuits or arbitration matters involving the company or its subsidiaries [3].

Core Viewpoint - The company announces that over 5% shareholder Jinghan Holdings Group's shares will be judicially auctioned due to a court ruling related to a loan dispute, with the auction scheduled for August 30-31, 2025 [1][4]. Group 1: Shareholder Auction Details - Jinghan Holdings Group will have 45,373,219 shares auctioned, representing 74.99% of their holdings and 5.95% of the company's total shares [1][3]. - The auction will take place on the Taobao judicial auction platform, with the court overseeing the process [2][4]. Group 2: Background of the Judicial Auction - The auction is a result of a lawsuit initiated by Cinda Asset Management Co., Ltd. against Jinghan Holdings Group due to a loan contract dispute, leading to a court judgment that holds Jinghan Holdings liable for certain payment obligations [4][5]. - The court's ruling allows Jinghan Holdings to seek reimbursement from its subsidiary after fulfilling its obligations [4]. Group 3: Impact on the Company - The auction process will not affect the company's governance structure or normal operations, and there will be no change in control [5][6]. - The company will continue to monitor the situation and fulfill its information disclosure obligations as required by the Shenzhen Stock Exchange [5][6].